Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $7.43.

Several brokerages have weighed in on TRVI. Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Raymond James assumed coverage on Trevi Therapeutics in a research note on Friday, August 30th. They set an “outperform” rating and a $9.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday, November 8th.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. The trade was a 4.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 21,595 shares of company stock worth $64,886 in the last three months. Corporate insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares in the last quarter. American Century Companies Inc. raised its position in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares during the period. MAI Capital Management lifted its holdings in Trevi Therapeutics by 0.7% during the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after purchasing an additional 8,789 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after purchasing an additional 11,450 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics during the first quarter worth about $47,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $2.75 on Wednesday. The firm has a market capitalization of $211.39 million, a P/E ratio of -6.25 and a beta of 1.01. Trevi Therapeutics has a one year low of $0.97 and a one year high of $4.00. The business has a fifty day moving average of $3.14 and a 200 day moving average of $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the company earned ($0.08) EPS. Analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.